A Phase 1, Open-Label, Multi-Center, Parallel Group Study to Assess the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function.

Trial Profile

A Phase 1, Open-Label, Multi-Center, Parallel Group Study to Assess the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Apr 2016

At a glance

  • Drugs Azacitidine (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 23 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Sep 2012 Planned end date changed from 1 Sep 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 27 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClincialTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top